We are live on ! Find out more
BLUE

bluebird bio
BLUE

Delisted

BLUE was delisted on the 30th of May, 2025.

Back to rankings

81 hedge funds and large institutions have $378M invested in bluebird bio in 2013 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 12

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

60% more capital invested

Capital invested by funds: $236M → $378M (+$142M)

21% more funds holding

Funds holding: 67 → 81 (+14)

Holders
81
Holders Change
+14
Holders Change %
+20.9%
% of All Funds
2.35%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
26
Increased
32
Reduced
16
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.1M
2
Capital Research Global Investors
Capital Research Global Investors
California
+$34.1M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.4M
4
BFA
BlackRock Fund Advisors
California
+$5.8M
5
FAM
Fred Alger Management
New York
+$5.12M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$6M
2
Ameriprise
Ameriprise
Minnesota
-$2.63M
3
PC
PointState Capital
New York
-$2.16M
4
QF
QVT Financial
New York
-$2.02M
5
PAM
Panagora Asset Management
Massachusetts
-$876K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
76
AllianceBernstein
Tennessee
$1K – – –
FNBT
77
FineMark National Bank & Trust
Florida
$1K +$559 +2 New
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$629 +$559 +2 New
Manulife (Manufacturers Life Insurance)
79
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$116 +$117K +418 +3,800%
O
80
OrbiMed
New York
– -$6M -17,177 Closed
QF
81
QVT Financial
New York
– -$2.02M -5,790 Closed
PAM
82
Panagora Asset Management
Massachusetts
– -$876K -2,509 Closed
PMAM
83
Picton Mahoney Asset Management
Ontario, Canada
– -$787K -2,254 Closed
Royal Bank of Canada
84
Royal Bank of Canada
Ontario, Canada
– -$351K -1,256 -100%
SIM
85
Spark Investment Management
New York
– -$406K -1,158 Closed
JP Morgan Chase
86
JP Morgan Chase
New York
– -$341K -975 Closed
DCM
87
Driehaus Capital Management
Illinois
– -$321K -919 Closed
EEG
88
E.E. Geduld
– -$270K -772 Closed
Nomura Holdings
89
Nomura Holdings
Japan
– -$237K -677 Closed
MLICM
90
Metropolitan Life Insurance Company (MetLife)
New York
– -$218K -624 Closed
GH
91
GAM Holding
Switzerland
– -$108K -309 Closed
SO
92
STRS Ohio
Ohio
– -$84K -239 Closed
PTC
93
Private Trust Company
Ohio
– +$559 +2 New
1 2 3
4

BLUE Hedge Fund Activity: Q4 2013 in Review

81 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2013, worth a combined $378M — up 60% from $236M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BLUE positions and 12 closed out — a net gain of 14 holders — while 32 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $43.1M. The largest seller was OrbiMed, exiting entirely with an estimated $6M sold.

  • 81 institutional investors held bluebird bio (BLUE) as of Q4 2013, up from 67 in Q3 2013.
  • Funds reported $378M of bluebird bio stock for Q4 2013, up 60% quarter-over-quarter.
  • 26 funds opened new bluebird bio positions in Q4 2013 and 12 closed out, a net change of +14 holders.
  • The largest bluebird bio buyer in Q4 2013 was Fidelity Investments, an estimated $43.1M added.
  • The largest bluebird bio seller in Q4 2013 was OrbiMed, an estimated $6M sold.

Based on aggregated 13F filings for Q4 2013.